Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stock Rating Reaffirmed by Stifel Nicolaus

Paterniano Del Favero
Agosto 13, 2017

Esperion Therapeutics earned a media sentiment score of 0.12 on Accern's scale. (NASDAQ:ESPR) by 6.1% during the second quarter, Holdings Channel reports. The fund owned 3,100 shares of the biopharmaceutical company's stock after selling 201 shares during the period. Equities research analysts predict that Esperion Therapeutics will post ($7.29) EPS for the current fiscal year. Jefferies Group LLC now has $55.00 target price on the biopharmaceutical company's stock, down from their previous target price of $85.00. Princeton Alpha Management LP acquired a new position in shares of Esperion Therapeutics during the first quarter worth $205,000. The biopharmaceutical company reported ($1.92) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.67) by $0.25. Nationwide Fund Advisors boosted its stake in Esperion Therapeutics by 2.4% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company's stock valued at $233,000 after buying an additional 6,000 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Esperion Therapeutics by 29.4% in the first quarter. Nationwide Fund Advisors now owns 39,286 shares of the biopharmaceutical company's stock worth $1,387,000 after buying an additional 921 shares during the last quarter. Institutional investors own 85.20% of the company's stock.

Examining Institutional Ownership at Esperion Therapeutics, Inc.

Aisling Capital Llc holds 4.77% of its portfolio in Esperion Therapeutics Inc for 1.64 million shares. 912,599 shares of the company traded hands. The company's 50-day moving average price is $47.09 and its 200-day moving average price is $35.27. Esperion Therapeutics, Inc. has a 52-week low of $9.40 and a 52-week high of $57.38. The total amount of shares outstanding is 21.99 million, giving the company a market capitalization of about 1.06 billion.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Tuesday, August 8th. During the same quarter in the prior year, the firm earned ($0.62) EPS. Jefferies Group also issued estimates for Esperion Therapeutics' Q4 2017 earnings at ($2.22) EPS, FY2017 earnings at ($7.96) EPS and FY2018 earnings at ($8.72) EPS. On Thursday, May 25 SWAN ROBERT HOLMES sold $875,000 worth of eBay Inc (NASDAQ:EBAY) or 25,000 shares. "(ESPR)" was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and global copyright & trademark laws.

A number of analysts have recently weighed in on ESPR shares.

Jefferies Group LLC upgraded shares of Esperion Therapeutics, Inc. UBS AG reiterated a "buy" recommendation and fixed a $57.00 price target (up from $52.00) on stocks of Esperion Therapeutics in a study report on early Tue, Jun 27th. Bank of America Corporation reaffirmed a "neutral" rating and set a $60.00 target price on shares of Esperion Therapeutics in a research report on Friday. Needham & Company LLC raised their price objective on shares of Esperion Therapeutics from $58.00 to $72.00 and gave the company a positive rating in a research report on Tuesday, August 8th. They issued a "buy" rating and a $48.00 price target on the stock. One research analyst has rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the company's stock. The company presently has an average rating of "Hold" and a consensus target price of $42.51.

WARNING: "Esperion Therapeutics, Inc". The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. The insider, GOLDSTEIN DOV A MD, now holds 837,125 shares of ESPR.

Altre relazioni OverNewsmagazine

Discuti questo articolo

SEGUI I NOSTRI GIORNALE